Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: A systematic review

Current Opinion in Ophthalmology

Volumn 21, Issue 3, 2010, Pages 218-226

  Schmucker, Christine ^a   Ehlken, Christoph ^a   Hansen, Lutz L ^a   Antes, Gerd ^a   Agostini, Hansjuergen T ^a   Lelgemann, Monika ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

Author keywords

Bevacizumab; Effectiveness; Ranibizumab; Safety

Indexed keywords

BEVACIZUMAB; ENDOTHELIAL CELL GROWTH FACTOR; RANIBIZUMAB; TRIAMCINOLONE;

CLINICAL PRACTICE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FOLLOW UP; HUMAN; LENS DISEASE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; REVIEW; TREATMENT OUTCOME; UVEITIS; VALIDITY; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; INJECTIONS; MACULAR DEGENERATION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 77951272899     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3283386783     Document Type: Review

References (53)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004; 291:1900-1901.
2. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82:844-851.
3. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye study: I. Outline and major prevalence findings. Am J Epidemiol 1977; 106:17-32.
4. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102:1640-1642.
5. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006; 355:1409-1412.
6. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36:331-335.
7. Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. York: University of York; 2001.
8. Brown D, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116:57-69.
9. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-1444.
10. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007; 144:850-857.
11. Bressler NM, Chang TS, Fine JT, et al. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol 2009; 127:13-21.
12. Suner IJ, Kokame GT, Yu E, et al. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci 2009; 50:3629-3635.
13. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006; 355:1419-1431.
14. Boyer DS, Antoszyk AN, Awh CC, et al., MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114:246-252.
15. Kaiser PK, Blodi BA, Shapiro H, et al. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114:1868-1875.
16. Chang TS, Bressler NM, Fine JT, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration. Arch Ophthalmol 2007; 125:1460-1469.
17. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008; 145:239-248.
18. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006; 113:633-642.
19. Bashshur ZF, Schakal A, Hamam RN, et al. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007; 125:1357-1361.
20. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007; 114:1179-1185.
21. Hahn R, Sacu S, Michels S, et al. Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular agerelated macular degeneration. Ophthalmologe 2007; 104:588-593.
22. Sacu S, Michels S, Prager F, et al. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye 2009; 23:2223-2227.
23. Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008; 92:356-360.
24. Abraham-Marin ML, Cortes-Luna CF, Alvarez-Rivera G, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefe's Arch Clin Exp Ophthalmol 2007; 245:651-655.
25. Aisenbrey S, Ziemssen F, Völker M, et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefe's Arch Clin Exp Ophthalmol 2007; 245:941-948.
26. Arias L, Caminal JM, Casas L, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008; 92:1636-1641.
27. Azad RV, Khan MA, Chanana B, et al. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population. Jpn J Ophthalmol 2008; 52:52-56.
28. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142:1-9.
29. Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008; 145:249-256.
30. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007; 143:510-512.
31. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA study): results of a phase 1 doseescalation study. Invest Ophthalmol Vis Sci 2006; 47:4569-4578.
32. Falkenstein IA, Cheng L, Morrison VL, et al. Standardized visual acuity results associated with primary versus secondary bevacizumab (Avastin) treatment for choroidal neovascularization in age-related macular degeneration. Retina 2007; 27:701-706.
33. Geitzenauer W, Michels S, Prager F, et al. Early effects of systemic and intravitreal bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Klin Monatsbl Augenheilkd 2006; 223:822-827.
34. Giansanti F, Virgili G, Bini A, et al. Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study. Eur J Ophthalmol 2007; 17:230-237.
35. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to agerelated macular degeneration. Graefe's Arch Clin Exp Ophthalmol 2007; 245:68-73.
36. Lazic R, Gabric N, Dekaris I, et al. Intravitreal bevacizumab (Avastin) in treatment of neovascular age-related macular degeneration. Coll Antropol 2007; 31 (Suppl 1):S315-S319.
37. Arias L, Caminal JM, Rubio M, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for predominantly classic choroidal neovascularization. Eur J Ophthalmol 2007; 17:992-995.
38. Cleary CA, Jungkim S, Ravikumar K, et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6-and 9-month results. Eye 2008; 22:82-86.
39. Furino C, Boscia F, Recchimurzo N, et al. Intravitreal bevacizumab for treatment-näve subfoveal occult choroidal neovascularization in age-related macular degeneration. Acta Ophthalmol 2009; 87:404-407.
40. Gelisken F, Ziemssen F, Voelker M, et al. Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration. Eye 2009; 23:694-702.
41. Goverdhan SV, Lochhead J. Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration. Br J Ophthalmol 2008; 92:210-212.
42. Jonas JB, Spandau UH, Rensch F, et al. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007; 23:240-242.
43. Jonas JB, Ihloff AK, Harder B, et al. Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration. Ophthalmic Res 2009; 41:21-27.
44. Levy J, Shneck M, Rosen S, et al. Intravitreal bevacizumab (Avastin) for subfoveal neovascular age-related macular degeneration. Int Ophthalmol 2009; 29:349-357.
45. Madhusudhana KC, Hannan SR, Williams CPR, et al. Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. Br J Ophthalmol 2007; 91:1716-1717.
46. Maier M, Feucht N, Haas K, et al. Intravitreal injection of bevacizumab for exudative AMD with occult or minimal classic choroidal neovascularisation (CNV). Klin Monatsbl Augenheilkd 2008; 225:818-824.
47. Melamud A, Stinnett S, Fekrat S. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol 2008; 146:91-95.
48. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe's Arch Clin Exp Ophthalmol 2008; 246:81-87.
49. Mangione CM. The National Eye Institute 25-item Visual Function Questionnaire (VFQ-25) version 2000. http://www.nei.nih.gov/resources/ visionfunction/ manual-cm2000.pdf[Accessed 12 November 2009].
50. IVAN study. www.controlled-trials.com. ISRCTN92166560 [Accessed 30 October 2009].
51. CATT study. www.clinicaltrials.gov. NCT00593450 [Accessed 30 October 2009].
52. EQUAL study: www.who.int/trialsearch.de. NTR1331 [Accessed 30 October 2009].
53. VIBERA study: www.clinicaltrials.gov. NCT00559715 [Accessed 30 October 2009].